

Publicazioni dal 1994 al 2014

- 1) Mariotti J, Maura F, Spina F, Roncari L, **Dodero A**, Farina L, Montefusco V, Carniti C, Sarina B, Patriarca F, Rambaldi A, Onida F, Olivieri A, Zallio F, Corradini P. Impact of Cytomegalovirus Replication and CMV serostatus on the Outcome of Patients with B-cell Lymphoma after Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2014 Feb 27. pii: S1083-8791(14)00102-5. PubMed PMID: 24583412.
- 2) Farina L, Spina F, Guidetti A, Longoni P, Ravagnani F, **Dodero A**, Montefusco V, Carlo-Stella C, Corradini P. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. *Leuk Lymphoma*. 2014 Feb;55(2):331-6. PubMed PMID: 23656194.
- 3) Montefusco V, Spina F, Patriarca F, Offidani M, Bruno B, Montanari M, Mussetti A, Sperotto A, Scortechini I, **Dodero A**, Fanin R, Valagussa P, Corradini P. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. 2013 Mar;19(3):424-8. PubMed PMID: 23142330.
- 4) Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, **Dodero A**, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM. Phase II study of sorafenib in patients with relapsed or refractory lymphoma. *Br J Haematol*. 2012 Jul;158(1):108-19. PubMed PMID: 22571717.
- 5) Rigacci L, Puccini B, **Dodero A**, Iacopino P, Castagna L, Bramanti S, Ciceri F, Fanin R, Rambaldi A, Falda M, Milone G, Guidi S, Martelli MF, Mazza P, Oneto R, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. *Ann Hematol*. 2012 Jun;91(6):931-9. PubMed PMID: 22245922.
- 6) Warncke M, Buchner M, Thaller G, **Dodero A**, Bulashevskaya A, Pfeifer D, Timmer J, Veelken H. Control of the specificity of T cell-mediated anti-idiotypic immunity by natural regulatory T cells. *Cancer Immunol Immunother*. 2011 Jan;60(1):49-60. PubMed PMID: 20848095; PubMed Central PMCID: PMC3029831.
- 7) **Dodero A**, Crocchiolo R, Patriarca F, Miceli R, Castagna L, Ciceri F, Bramanti S, Frungillo N, Milani R, Crippa F, Fallanca F, Englaro E, Corradini P. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. *Cancer*. 2010 Nov 1;116(21):5001-11. PubMed PMID: 20665491.
- 8) Farina L, Carniti C, **Dodero A**, Vendramin A, Raganato A, Spina F, Patriarca F, Narni F, Benedetti F, Olivieri A, Corradini P. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. *Haematologica*. 2009 May;94(5):654-62. PubMed PMID: 19377072; PubMed Central PMCID: PMC2675677.
- 9) **Dodero A**, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, Carlo-Stella C, Di Terlizzi S, Milanese M, Longoni P, Gandola L, Lombardo C, Corradini P. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. *Blood*. 2009 May 7;113(19):4771-9. PubMed PMID: 19211934.

- 10) Corradini P, **Dodero A**, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. *Leukemia*. 2007 Nov;21(11):2316-23. PubMed PMID: 17597807.
- 11) Paolo C, Lucia F, **Anna D**. Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. *Leuk Lymphoma*. 2007 Aug;48(8):1496-501. Review. PubMed PMID: 17701579.
- 12) Warncke M, **Dodero A**, Dierbach H, Follo M, Veelken H. Murine dendritic cells generated under serum-free conditions have a mature phenotype and efficiently induce primary immune responses. *J Immunol Methods*. 2006 Mar 20;310(1-2):1-11. Epub 2005 Oct 25. PubMed PMID: 16337648.
- 13) Corradini P, Zallio F, Mariotti J, Farina L, Bregni M, Valagussa P, Ciceri F, Bacigalupo A, **Dodero A**, Lucesole M, Patriarca F, Rambaldi A, Scimè R, Locasciulli A, Bandini G, Gianni AM, Tarella C, Olivieri A. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. *J Clin Oncol*. 2005 Sep 20;23(27):6690-8. PubMed PMID: 16170177.
- 14) **Dodero A**, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V, Farina L, Milanese M, Longoni P, Carlo-Stella C, Corradini P. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. *Exp Hematol*. 2005 Aug;33(8):920-7. PubMed PMID: 16038785.
- 15) Corradini P, **Dodero A**, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. *J Clin Oncol*. 2004 Jun 1;22(11):2172-6. PubMed PMID: 15169805.
- 16) Cocconi G, Franciosi V, **Dodero A**, Bologna A, Vasini G, De Lisi V, Di Blasio B, Ceci G, Camisa R, Cascinu S. P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study. *Am J Clin Oncol*. 2003 Dec;26(6):535-42. PubMed PMID: 14663368.
- 17) **Dodero A**, Perfetti V, Ciceri F, Corradini P. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma. *Haematologica*. 2002 Dec;87(12):ECR41. PubMed PMID: 12495912.
- 18) Bregni M, **Dodero A**, Peccatori J, Pescarollo A, Bernardi M, Sassi I, Voena C, Zaniboni A, Bordignon C, Corradini P. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. *Blood*. 2002 Jun 1;99(11):4234-6. PubMed PMID: 12010834.
- 19) Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, **Dodero A**, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. *Blood*. 2002 Jan 1;99(1):75-82. PubMed PMID: 11756155.

- 20) Bregni M, Siena S, Di Nicola M, **Dodero A**, Peccatori F, Ravagnani F, Danesini G, Laffranchi A, Bonadonna G, Gianni AM. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. *J Clin Oncol*. 1996 Feb;14(2):628-35. PubMed PMID: 8636780.
- 21) Di Nicola M, Siena S, Bregni M, Ravagnani F, Vitello F, Belli N, **Dodero A**, Magni M, Bonadonna G, Gianni AM, et al. Large-scale enrichment of mobilized CD34+ peripheral blood hematopoietic progenitors by removal of nylon wool-adherent mature cells. *Bone Marrow Transplant*. 1994 Dec;14(6):863-9. Erratum in: *Bone Marrow Transplant* 1995 Aug;16(2):327. PubMed PMID: 7536068.